Tony Kouzarides, Founder of STORM Therapeutics, Awarded British Knighthood for Services to Healthcare Innovation and Delivery [Yahoo! Finance]
Danaher Corporation (DHR)
Last danaher corporation earnings: 1/30 06:00 am
Check Earnings Report
US:NYSE Investor Relations:
investors.danaher.com
Company Research
Source: Yahoo! Finance
CAMBRIDGE, England June 17, 2024 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, is delighted to announce that its Founder & Director and Professor of Cancer Biology, University of Cambridge , UK, Tony Kouzarides, PhD, FMedSci, FRS, will be honored with a Knighthood for his global impact on disease treatment. Professor Kouzarides, a world leading cancer biologist with a career spanning over 25 years, will be awarded the knighthood at the King's Birthday Honors, 2024, Investiture ceremony. Professor Kouzarides has been dedicated to the conversion of science into patient benefit throughout his career. STORM Therapeutics was spun out from the University of Cambridge in 2015 by Professor Kouzarides and his colleague Professor Eric Miska , following their groundbreaking work in RNA epigenetics. Professor Kouzarides and his research group identified the importance of RNA modificati
Show less
Read more
Impact Snapshot
Event Time:
DHR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DHR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DHR alerts
High impacting Danaher Corporation news events
Weekly update
A roundup of the hottest topics
DHR
News
- Danaher Co. (NYSE: DHR) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Danaher Schedules Second Quarter 2024 Earnings Conference CallPR Newswire
- Global Rubella Diagnostic Testing Market Size To Worth USD 2.23 Billion By 2033 | CAGR Of 5.15% [Yahoo! Finance]Yahoo! Finance
- Did Danaher Corporation (DHR) Get a Good Analyst Rating for Its Q1 Performance? [Yahoo! Finance]Yahoo! Finance
- Integrated DNA Technologies Introduces New HIV Panel to Advance Virology Research [Yahoo! Finance]Yahoo! Finance
DHR
Earnings
- 4/23/24 - Beat
DHR
Sec Filings
- 6/20/24 - Form 8-K
- 6/7/24 - Form 11-K
- 5/17/24 - Form 4
- DHR's page on the SEC website